Statin therapy for ASCVD prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 7: | Line 7: | ||
[[File:ACCAHA cholesterol treatment algorithm.jpg|900px]] | [[File:ACCAHA cholesterol treatment algorithm.jpg|900px]] | ||
===Initial evaluation prior to statin initiation== | |||
Initial evaluation prior to statin initiation include: | Initial evaluation prior to statin initiation include: | ||
*Fasting lipid panel | *Fasting lipid panel | ||
Revision as of 21:18, 27 October 2016
Template:Hypercholesterolemia Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Major Recommendations for Statin Therapy for ASCVD Prevention
The following is a treatment algorithm proposed by the AHA/ACC guidelines committee:[1]
=Initial evaluation prior to statin initiation
Initial evaluation prior to statin initiation include:
- Fasting lipid panel
- Fasting lipid panel preferred. In a nonfasting individual, a non–HDL-C level !220 mg/dL could indicate genetic hypercholesterolemia that requires further evaluation or a secondary etiology. If nonfasting triglycerides are !500 mg/dL, a fasting lipid panel is required.
- ALT
- CK
- Consider evaluation for other secondary causes
References
- ↑ Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH; et al. (2014). "2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. 129 (25 Suppl 2): S1–S45. doi:10.1161/01.cir.0000437738.63853.7a. PMID 24222016.